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Simple Summary: CAR T cells are a type of immunotherapy whereby a patient’s own cells are
genetically modified to recognise and kill the patient’s own cancer cells. Currently, each patient has
CAR T cells made from their own blood cells. This type of therapy has had a big impact on the
treatment of blood cancers, however making an individual treatment from each patient is expensive
and labour intensive. This review discusses the potential of making CAR T cells more widely
available by producing them in large numbers from healthy donors.
Abstract: CAR T cells have revolutionised the treatment of haematological malignancies. Despite
this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use
of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in
large variation in the product, greater wait times for treatment and higher costs. To overcome this
several novel approaches have emerged that utilise allogeneic cells, so called “off the shelf” CAR T
cells. In this Review, we describe the different approaches that have been used to produce allogeneic
CAR T to date, as well as their current pre-clinical and clinical progress.
Keywords: CAR T cell; immunotherapy; adoptive cell transfer
1. Introduction
It has long been recognised that the immune system plays a vital role in the estab-
lishment and progression of tumours [1–3]. In healthy individuals, the immune system
seeks out and destroys malignant cells before they form established tumours. Nevertheless,
tumours do form in immunocompetent individuals, and the possible process by which
this develops is described by the immunoediting hypothesis [4]. Briefly, it comprises three
phases: elimination, equilibrium, and escape. During the Elimination phase the immune
system destroys transformed cells faster than they can grow back. The Equilibrium phase
sees the rate of destruction of transformed cells matching their proliferative capacity. Fi-
nally, the selective pressure of immune attack results in selection for and growth of resistant
cells who exhibit immune escape and the tumour progresses. Due to the pivotal role of
the immune system in cancer progression, immunotherapy has again attracted significant
attention in the last few years. Immunotherapy modulates the patients’ immune system to
promote or enhance cancer cell recognition and killing. Immunotherapy can be split into
two areas, active immunotherapies, which further stimulate the patients’ existing effector
function, and passive therapies, which compensate for a lack of host effector function.
Active immunotherapies, such as checkpoint inhibitors, have failed to bring about the
population-wide improvement in cancer therapy that was hoped for but have generated
impressive responses in a much smaller fractions of treated patients [5,6]. This is probably
due to a combination of factors that are becoming clearer as these disappointing responses
have arisen.
Mutational load present in the tumour is predictive of immune checkpoint blockade
response, with patients with more mutations or microsatellite-instability having improved
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survival and more durable responses [7]. Similarly, mismatch repair deficiency can result
in greater responses to checkpoint inhibitors, possibly due to the enhanced number of neo-
antigens produced as a result of such deficiency [8]. More recently, the gut microbiome has
been implicated in the response to active immunotherapies. The microbiome plays a role
in activating the innate immune system against the tumour [9,10]. MHC I downregulation
is prevalent in many cancers and allows the cancer cells to evade immune cell recognition,
even in combination with checkpoint inhibitors [6]. The HLA subtype expressed by a
patient can also affect the efficacy of active immunotherapies, especially cancer vaccines [11].
Tumour infiltrating lymphocyte (TIL) infiltration present in the tumour is also predictive of
positive response to active immunotherapies [12–16].
To overcome this lack of active effector cells within the patient, adoptive cell therapies
(ACT) have been investigated, whereby effector cells are introduced to the patient to
destroy the cancer [17]. The earliest studies from Steve Rosenberg investigated the systemic
administration of lymphokine-activated killer cells (patient lymphocytes cultured ex-vivo
in the presence of IL-2 then re-infused) and IL-2 in patients with metastatic cancer. This
resulted in some partial responses and one patient with complete tumour regression [18].
In later studies, tumour infiltrating lymphocytes (TIL) were isolated from patients and
expanded ex-vivo before reinfusing them back into the same patient at higher numbers [19].
The first clinical trial using TILs to treat metastatic melanoma showed an overall objective
response rate of 34%. Side effects included oedema, respiratory distress and disorientation,
but are thought to have been partially caused by the IL-2 administered as part of the
treatment regimen [20]. To improve the potency of the T cell response and to redirect them
towards a specific target, TCR therapy and chimeric antigen receptor (CAR) T cells were
developed [21]. CAR T cells are T cells that are modified to express an artificial T cell
receptor called a chimeric antigen receptor (CAR) that is designed to redirect the T cell
towards a specific cancer cell antigen.
Conventionally CAR T cells are produced from the patient’s own T cells, isolated
from the peripheral blood, genetically modified to express a CAR with specificity for a
designated target antigen and then reinfused into the patient following lymphodepletion.
These cells can recognise cell surface antigens in an MHC- independent manner allowing a
wider range of antigens to be targeted. The structure of the CAR differs to the conventional
T cell receptor (TCR) that is composed of a TCR heterodimer. CARs are composed of
several distinct regions each with a unique function [22]. The extracellular domain of
the CAR contains antigen recognition domain that is able to bind to the target expressed
on the cancer cells. This binding domain is typically a single chain variable fragment
(ScFv) against the target but can also be derived from a ligand or peptide (such as the
A20FMDV2 peptide that binds to αvβ6) that binds specifically to the antigen [23,24]. This
domain is followed by a hinge region that provides physical flexibility for the CAR and
facilitates the formation of the immune synapse [25]. The transmembrane domain connects
the extracellular domain of the receptor with the intracellular domain and allows signal
transduction into the cell. The intracellular domain composition represents the most varied
part of the CAR as it is mostly here that the various generations of CARs vary between
each other. Thus the first generation CARs only contained a single signalling domain,
usually CD3 zeta, which is responsible for the cytotoxic activity of the cell [26]. Subsequent
generations of CARs also contain one or more co-stimulatory domains (usually 4–1BB
or CD28) which provided pro-survival signals and improved persistence of the CAR
T cells [27].
2. Autologous and Allogeneic CAR T Cells
CAR T cells have revolutionised the treatment of haematological malignancies, with
three CD19 targeting CARs licenced for use [28–30]. However, these successes are yet
to be translated into solid cancers. One of the obstacles to scalable CAR T cell treatment
of both liquid and solid cancers is the requirement of autologous T cells, which imposes
several problems. Firstly due to the small scale production, the cost per patient is extremely
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high, up to $475,000 [31]. This also makes the production extremely labour intensive as
each patient must have CAR T cells made individually for them. Due to this personalised
approach the manufacturing time for CAR T cell is around three weeks [32]. This is often
too long for patients to wait for the treatment and by the time they receive the CAR T cells,
significant disease progression may have occurred [33]. Moreover, patients with advanced
cancer are often lymphopenic due to disease burden and prior therapy, with residual T
cells of poor quality and function [34]. This effect is compounded by the fact that T cells
from these patients may have also been in contact with the immunosuppressive tumour
microenvironment [34]. In the ELIANA study of a CD19 targeting CAR for B-ALL, 7.6% of
patients did not receive the CAR T cells due to ‘product related issues’, whereby it was not
possible to manufacture a sufficient number of CAR T cells for infusion [35]. In another
trial of a CD19 CAR for the treatment of B-cell Precursor Acute Lymphoblastic Leukemia
9% of patients did not receive CAR T cells product due to manufacturing issues [36]. This
illustrates the issues with using autologous T cells for effective anti-cancer therapy.
The use of different cells for each recipient, namely autologous cells from each patient,
can result in a large variation between the quality of the CAR T cells produced, making dos-
ing and efficacy hard to compare. Patients who don’t respond to CAR T cell therapy tend to
have received products with a more differentiated effector T cell phenotype, whereas those
who respond better often have an early memory phenotype [37]. In addition, expression of
certain receptors on the T cell used to produce the CAR T can confer a more efficacious
product; for example, expression of the IL-6 receptor is favourable [37]. The low number
of CAR T cells made from autologous donation also means that re-dosing with the same
product is not usually possible and patients must undergo the same process multiple times
if repeated administration is required.
Conceptually, these obstacles can be overcome by using allogeneic T cells as the basis
for producing CAR T cells. This “off the shelf product” made from donor T cells could be
produced on an industrial scale from donors with an ideal T cell phenotype. This would
produce a superior product that could be administered immediately with easy re-dosing.
This would also allow patients to be treated with multiple CAR T cells simultaneously,
targeting different antigens, to improve efficacy and prevent tumour resistance. Above all
it would greatly reduce the manufacturing costs making it more accessible to patients [38].
However, there are also some difficulties inherent in the development of allogeneic
CAR T cell products. The main hurdle is graft versus host disease (GvHD) which occurs
when the allogeneic T cells recognise the host’s cells as foreign and mount an immune
response against them. This is mediated through the action of the allogeneic T cell receptor
against the host HLA. GvHD can be fatal and has been a major obstacle to successful
allogeneic haematopoietic stem cell transplantation (HSCT) [39].
Conversely, the host immune system may recognise the donor T cells as foreign
causing rejection and destruction of the CAR T cells, terminating the therapeutic effect.
One of the main requirements for effective CAR T cell immunotherapy is persistence of
the infused cells within the patient. CD19 CAR T cells have been detected in the blood
of patients several years after treatment [39,40]. Due to the foreign nature of allogeneic T
cells, they have poorer persistence in vivo and consequently may not result in sustained
responses. To allow allogeneic T cells to survive and have anti-cancer effects in the patient,
several approaches can be taken. A list of ongoing allogeneic CAR T cell clinical trials is
provided in Table 1. Approaches to develop off the shelf CAR cell therapies are discussed
in greater detail in the sections that follow.
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Table 1. Past and current clinical trials involving allogeneic CAR cell therapies for the treatment of cancer.
Cell Type CAR Target Modification Disease Trial Number Gene EditingTechnology
γδ T cells CD19 Leukaemia, Lymphoma NCT02656147 NS
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Table 1. Cont.


































































Multiple Myeloma NCT04244656 CRISPR-Cas9
T cells CD19 Unknown Acute LymphoblasticLeukaemia NCT04154709 CRISPR-Cas9
T cells CD22 TRAC disrupted B-cell AcuteLymphoblastic Leukaemia NCT04150497 TALENs
T cells CD19 Unknown Diffuse Large B-cellLymphoma NCT04026100 CRISPR-Cas9
T cells CD19 + CD20 orCD19+CD22 Unknown
B Cell Leukaemia, B Cell
Lymphoma NCT03398967 CRISPR-Cas9
T cells CS1 TRAC disrupted Relapsed/RefractoryMultiple Myeloma NCT04142619 TALENs










T cells CD22 Unknown B Cell Malignancy NCT04601181 NS
T cells CD19 Unknown B Cell Malignancy NCT04384393 NS
Cancers 2021, 13, 1926 6 of 18
Table 1. Cont.
Cell Type CAR Target Modification Disease Trial Number Gene EditingTechnology
T cells Unknown Unknown Ovarian Cancer NCT00019136 NS
T cells CD70
B2M KO and CAR
insertion into
TRAC locus
T Cell Lymphoma NCT04502446 CRISPR-Cas9
T cells CD19 Unknown ALL, Childhood B-Cell NCT04173988 NS
T cells GD2 Tri-virus specificcytotoxic T cells Neuroblastoma NCT01460901 NS
T cells CD20 CAR inserted intoTCR locus
Non-Hodgkin’s
Lymphoma, NCT04030195 NS
T cells CD19 TRAC locusdisrupted
B Acute Lymphoblastic
Leukaemia NCT04557436 CRISPR-Cas9






T cells CD20 Unknown


















Renal Cell Carcinoma NCT04438083 CRISPR-Cas9





NKT cells CD19 Lymphoma NCT03774654 NS
NK cells CD19 NK-92 cells Leukemia NCT02892695 NS
NK cells CD7 pNK cells Leukemia NCT02742727 NS
NK cells CD19 CB-NK CD19 Positive Lymphoma NCT03579927 NS









NK cells CD33 NK-92 Leukaemia NCT02944162 NS
NK cells BCMA NK-92 Multiple Myeloma NCT03940833 NS
NK cells CD19 NK-92 Leukaemia, Lymphoma NCT02892695 NS
NK cells NKG2D ligands Solid Tumours NCT03415100 NS
NK cells NKG2D ligands Membrane IL-15 Relapsed/RefractoryAML NCT04623944 NS
Abbreviations: TRAC, T cell receptor alpha locus. NS, Not stated.
Cancers 2021, 13, 1926 7 of 18
3. γδ. T Cells
An emerging field is the use of different T cell subtypes to produce CAR T cells.
Conventionally αβ T cells have been used for production of CAR T cells, however, more
recently there has been significant interest around using γδ T cells instead as they have
advantages over αβ T cells.
γδ T cells represent a small percentage of total T cells, around 2% of peripheral
blood T cells [41,42], however they constitute a large proportion of tissue resident T cells,
especially in the gut mucosa [43]. The TCR heterodimer of γδ T cells is made up of
a γ subunit and a δ subunit in contrast to the α and β subunit present in αβ T cells.
Both T cell types are capable of strong cytotoxic effector function via both death receptor
interactions and release of cytolytic granules [44]. Additionally, they can release a wide
range of inflammatory cytokines including TNFα and IFNγ [44]. Notably γδ T cells are
also able to process and present antigens to CD4 and CD8 T cells in a similar manner to
professional antigen presenting cells (APC) [45]. There are two main subtypes of γδ T cell.
Vδ2 T cells are the most common subtype and constitute the majority of circulating γδ T
cells. In contrast, non-Vδ2 cells are more common in mucosal sites [46,47]. Subsets of both
αβ and γδ T cells are able to recognise lipid antigens presented on CD1 proteins via their
respective TCR [48–50].
γδ T cells are a key component of the innate immune system that help to detect and
eradicate tumour cells [51]. The γδ TCR recognise unprocessed antigens and do not rely on
MHC presentation for antigen recognition in contrast to most αβ T cells, which recognise
processed peptide antigens presented on MHC-I [52]. This means γδ T cells can target
many different antigens not recognised by the αβ subset. Additionally, they show less
toxicity towards healthy cells than αβ T cells [53,54].
Similarly to NK and CD8+ αβ T cells cells, γδ T cells express NKG2D on their surface.
This receptor is key in identifying malignant cells and provides a co-stimulatory signal via
DAP10 [55]. NKG2D recognises several UL16-binding proteins, which are upregulated in
stressed and transformed cells [56], as well as an MHC class I polypeptide-related sequence
A and B (MICA/B) (Figure 1) [57]. This allows the cells to identify transformed cells in an
alternative way to expression of a specific antigen. DNAM-1(DNAX accessory molecule-1)
is another activation receptor expressed on γδ T cells that bind to poliovirus receptor
(PVR/CD155), and Nectin-2 ligands, which are commonly upregulated on tumour cells
(Figure 2) [58,59]. The Vγ9Vδ2 T cell receptor is expressed on the main circulating γδ
T cell subset and is capable of identifying phosphorylated antigens (pAgs), products of
mevalonate metabolism that are frequently overproduced in transformed and infected
cells (Figure 2) [60]. Not only cell surface antigens are targetable with γδ T cells, soluble
proteins within the TME can also be recognised, further increasing their range of action
(Figure 1) [61]. Further arming the γδ T cells with a CAR construct can allow targeting of
specific cell surface antigens and increased cytotoxicity [62]. Activated γδ T cells induce a
wide range of immune responses, recruiting αβ T cells, APCs and B cells and providing
costimulatory signals to NK cells [63,64].
Despite the small starting number of γδ T cells present in peripheral blood, these
cells can be expanded ex vivo to produce clinically significant numbers that can be used
therapeutically [65]. They are unlikely to induce GvHD because the activation of their
TCR is not MHC restricted. CAR γδ T cells directed towards the disialoganglioside GD2,
which is frequently overexpressed in gliomas and other tumours of neuroectodermal
origin, enhance cytotoxicity against GD2-expressing cell lines. γδT expressing a CAR
targeting CD19 for leukaemia treatment showed cytotoxicity towards CD19+ tumour
cell lines in vitro and in vivo. They also demonstrated a CAR independent effect against
CD19- clones [62]. There is currently a study ongoing which is examining the feasibility
of γδ T cell expansion from peripheral blood of AML patients and if these cells will
tolerate modification with a CAR (NCT03885076). A phase 1 trial investigating the safety
of γδ T cells with a NKG2DL-targeting CAR in solid tumours is currently underway
(NCT04107142). This study is using both haploidentical and allogeneic γδ T cells (Table 1).
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Figure 1. Diagram illustrating some of the main receptors present on NK cells, αβ T cells and γδ T 
cells and their corresponding ligands that are involved in tumour cell recognition and killing. NK 
cells express a variety of receptors that allow them to recognize tumour cells, the FcyR receptors 
recognised the constant region of antibodies what bind to TAA’s on tumour cells. NKG2D ex-
pressed on both NK cells and γδ T cells, has a variety of ligands, including UL16-binding proteins 
and MICA/B. NKG2C recognizes HLA-E expressed on tumour cells. NKp30 can bind B7-H6 and 
NKp46 mediates tumour directed killing via an unknown ligand. αβ T cells express a αβ TCR 
which recognises peptide antigens that are sampled from inside the tumour and presented on 
HLA-I molecules. Both αβ and γδ TCRs can also recognise lipid antigens expressed on CD1. Addi-
tionally, γδ T cells also express DNAM-1 which recognises PVR/CD155 and Nectin-2. Unlike the 
αβ TCR, the γδ TCR can recognise soluble protein and is not restricted to recognizing antigen pre-
sented on HLA. 
 
Figure 2: Diagram illustrating genetic modifications that can be made to donor αβ T cells to make 
allogenic CAR T cell therapy possible. To prevent GvHD the αβ TCR must be disrupted. This can 
be achieved by inserting the CAR construct into the TRAC locus or by knocking down the TRAC 
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4. NK Cells
Natural killer (NK) cells also represent an attractive cellular vehicle for the develop-
ment of off-the-shelf CAR cell therapy. NK cells play an important role in anti-tumour
immunity and exert cytolytic activity against cancer cells via the release of granzyme B
and perforin as well as the action of the Fas ligand. NK cells do not express an antigen
specific cell surface receptor, but instead have more wide-ranging anti-tumour action
mediated by several innate receptors [66]. NK cells express inhibitory receptors such as
killer immunoglobulin-like receptor (KIR) which recognise classical HLA class I molecules
such as HLA-A to prevent NK cell activity against healthy cells (Figure 2) [67]. Binding of
inhibitory KIR to self HLA class 1 prevents NK cell effector function [68,69]. Contrastingly,
killer cell activating receptors (KARs) can recognise a host of ligands on tumour cells;
for example NKG2C (CD94) recognises non- classical HLA class I molecules including
HLA-E (Figure 2) [70]. Tumour cells often downregulate the expression of HLA molecules,
resulting in recognition and activation by NK cells.
Another important anti-tumour role of NK cells is via antibody-dependent cell-
mediated cytotoxicity (ADCC). The ADCC receptor complex is able to bind with the
Fc domain of human immunoglobulin via FcyRIIIA (CD16a) and FcγRIIC/CD32c and
cause NK cell activation [71–73] (Figure 2). This mechanism allows NK cells to detect
and kill tumour cells that have been opsonised with antibodies [74]. This is one of the
mechanisms underlying the effectiveness of monoclonal antibody therapy of cancer [75,76].
Activatory receptors cause activation of NK cells, due to the presence of immunoreceptor
tyrosine-based activation motifs (ITAMs) in the endodomain of the complexes [77]. ITAMs
consist of a tandemly repeated four amino acid motif that provide an important initiating
component in the activation of immune cells.
NK cells do not induce GvHD due to the lack of TCR expression and allogeneic NK
cells have been successfully transferred to patients without toxicity [78]. They also show
a much more favourable toxicity profile compared to adoptively infused CAR T cells,
with cytokine storm and neurotoxicity rarely seen [79]. This may be due to differences
in cytokine release between T cells and NK cells, but this is not yet fully understood.
The MHC1 mismatch between the donor cells and the tumour may also cause increased
cytotoxicity against the tumour [80].
Although NK cells have innate anti-cancer activity, further arming them with a CAR
directs their action towards a specific antigen. In addition to direct CAR mediated cytotox-
icity, NK CARs can also perform (ADCC) and can also recognise cancerous cells via the
action of their other cancer-directed receptors (see above) making them an appealing cell
type for CAR therapy.
Production of CAR NK cells is much more challenging than CAR T cells due to the lower
numbers of NK cells present in the blood and their reduced capacity for expansion [81,82].
Additionally NK cells are also less amenable to genetic manipulation than T cells making
them more challenging to work with as an adoptive cell transfer therapy [83]. It is however
possible to obtain NK cells from frozen umbilical cord blood (UBC) and this approach has
been used to create NK cells expressing a CD19 targeting CAR [84]. This approach has been
used in a phase I and II clinical trial which demonstrated the feasibility of the transduction
and expansion of NK cells as a therapy. Anti-CD19 CAR-NK cells derived from cord blood
were used to treat relapsed or refractory CD19-positive cancers, with 7 out of 11 patients
showing a complete response [85].
NK-92 cells, an activated human NK line has also been safely used in patients [86]. The
human NK-92 line was derived from a 50-year-old male patient with non-Hodgkin’s lym-
phoma and has shown cytotoxic activity against both haematological and non-haematological
cancer cells in-vitro [87]. NK-92 cells don’t express KIRs and are therefore more active as
they don’t receive inhibitory signals from the cancer cells [88]. Just as with primary NK
cells, NK-92 cells can be further modified to express CARs to target specific tumour antigens.
CD20-targeting CAR NK-92 cells showed efficacy in vitro against lymphoma and leukaemia
cells [89]. In a murine model of lymphoma, tumour growth was significantly reduced follow-
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ing treatment with CD20 targeting CAR NK-92 cells compared to those treated with parental
NK-92 cells. This also resulted in improved survival in the CAR NK-92 group.
NK-92 cells have also been redirected to target ErbB2 in breast cancer cell lines [90,91];
SKBR3 breast cancer cells were specifically lysed by NK-92- ErbB2 targeting CAR cells
compared to NK-92 parental cells in-vitro. NK-92 cells modified to express an anti-PSMA
CAR have shown promising results in a preclinical model of prostate cancer. NK-92 cells
expressing an anti-PSMA CAR significantly reduced the tumour size and significantly
increased survival compared to unmodified NK-92 cells in an orthotropic PC-3 model of
prostate cancer [92]. NIH 3T3 fibroblasts expressing oncogenic human ErbB2 treated with
NK-92- ErbB2 targeting CAR cells resulted in a reduction in tumour growth in a xenograft
model compared to tumours treated with unmodified NK-92 [90].
NK CARs targeting EGFR, derived from both NK-92 cells and primary NK cells from
healthy donors, demonstrated activity against glioblastoma cell lines [91]. EGFR-CAR-
transduced NK-92 cells have significantly greater cytotoxic activity against EGFR positive
glioblastoma cell lines compared to mock-transduced NK cells. These EGFR-CAR NK-92
cells also significantly reduced tumour growth and extended survival in two orthotopic
xenograft models of glioblastoma. Primary NK cells transduced with EGFR-CAR also
showed enhanced cytotoxicity against patient-derived glioblastoma cell lines in-vitro. CD33
CAR expressing NK-92 cells showed no significant adverse side effects in a phase 1 trial
for the treatment of acute myeloid leukaemia (AML) (NCT02944162) [93] (Table 1). Taking
the concept of an off-the-shelf CAR even further, a universal CAR NK-92 cell has been
developed [94]. This universal CAR (UniCAR) does not target tumour antigens directly,
but are redirected using a tumour-specific target module [95]. This method allows the
targeting of multiple tumour antigen using the same CAR, by utilizing different targeting
modules. When NK-92 expressing the UniCAR were combined with a GD-2 targeting
module they specifically lysed neuroblastoma and melanoma cells expressing GD-2 in-
vitro [94]. Similarly, an adapter CAR (AdCAR) system whereby the CAR recognizes biotin
and uses biotinylated antibodies as targeting modules has been used in NK-92 cells to
target multiple tumour antigen in in-vitro models of non-Hodgkin’s lymphoma (NHL),
mantle-cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL) [96].
Use of the NK-92 cell line is particularly beneficial as it removes the need for isolation
of primary NK cells from healthy donors and has unlimited potential for cell number.
However, as NK-92 cells are derived from non-Hodgkin’s lymphoma, the cells are normally
irradiated prior to infusion into patients to prevent any possibility malignant expansion [87].
Therefore, a limitation of using these cells as a carrier of a CAR is that the irradiation
prevents proliferation of the NK-92 cells and impacts their longevity [97,98].
5. Invariant NK T Cells
Taking this principle further, NK T cells are a type cytotoxic immune cell that share
features of both NK cells and T cells. Both NK cells and NK T cells can recognise and
destroy cancer cells without prior exposure to these cells. They differ in that NK cells
contain cytoplasmic granules containing granzyme B and perforin but NK T cells do
not [99]. NK cells express both Fc receptors and inhibitory receptors that are not present on
NK T cells and similarly the NK T cells express a TCR, which is not present on NK cells.
A subset of NK T cells called ‘invariant NKT cells’ (iNKT cells) are able to recognise
lipid antigens presented by CD1d on B cells, APCs and epithelial cells [100]. These lipid
antigens are recognised through a very specific TCR expressed by the iNKT cells. Allogeneic
iNKT cells have been shown to be protective against GvHD due to the production of IL-4
and promotion of a Th2-biased immune response, making them an attractive candidate
for allogeneic CAR T cell therapy [101–103]. iNKT cells expressing a CD19 targeting CAR
have shown both in-vitro and in-vivo efficacy against lymphoma cells expressing both
CD19 and CD1d. In a murine model of CD1d+CD19+ B cell malignancy, the CAR19-iNKT
cell-treated group displayed a significantly improved overall and tumour-free survival
compared to those treated with conventional CAR19-T cells [104]. Anti-GD2 CAR-NKT
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cells have shown anti-tumour effects against neuroblastoma cells in-vitro and in-vivo. The
NKT cells showed a lower toxicity profile compared to T cells expressing the same CAR,
with the CAR T cells causing lethal GvHD in humanised NSG mice [105].
A phase 1 trial is currently underway assessing the safety of a GD2 CAR and IL-15
expressing autologous NKT Cells to treat children with neuroblastoma (NCT03294954).
Similarly, a CD19 NKT CAR produced from allogeneic cells is currently being assessed in a
phase 1 trial for the treatment of B cell malignancies (NCT03774654) (Table 1).
6. Genome Editing of αβ T Cells
Conventional αβT cells can also be used as the basis to generate allogeneic CAR T cells.
However, they must first be modified to inactivate their capacity to induce TCR-dependent
GvHD. To ensure this, the αβ TCR must be removed from the cell surface to prevent the T
cells reacting against the host. To achieve this, it is sufficient to knockout the gene encoding
the alpha chain (TRAC). This prevents the association of αβ heterodimer with CD3γ,δ,ε
and ζ subunits, a process that is essential for cell surface expression of this complex.
Several genome editing techniques have been used to disrupt the αβ TCR includ-
ing Zinc finger nucleases (ZFNs), CRISPR/Cas9 and Transcription activator-like effector
nuclease (TALEN). However, these techniques do not result in complete knock out of
both alleles in all target cells, with the result that some cells expressing residual αβ TCR
may be introduced into the patient. This could result in GvHD, so additional rounds of
selection are often required [106]. There is also a risk of off target genome cleavage and/or
translocation formation, which could theoretically confer oncogenic potential on the CAR
T cells [107]. The production of αβ CAR T cells is usually performed using a two-step
technique where the gene encoding the CAR is integrated into the T cell using a viral vector
followed by nuclease disruption of the TRAC loci (Figure 2).
This degree of genetic modification of primary cells can be problematic due to
manipulation-related toxicity and poor transduction efficiency. However, a technique
has been developed recently whereby the CAR construct is integrated into the TRAC locus.
This simultaneously disrupts the αβ TCR and promotes CAR expression, meaning there
are no CAR T cells produced that express the TCR [108,109]. This same result has also been
achieved by combining the CAR construct and the CRISPR/Cas9 guide RNA in the same
vector. This results in knock out of the αβ TCR in cells expressing the CAR (Figure 2) [110].
There is evidence that these αβ TCR negative cells have superior anti-tumour activity
compared to traditional CAR T cells containing the native αβ TCR. Sadelain argued that
this may be due to a reduction in tonic signalling from the TCR [107]. However, long term
in-vivo persistence of TCR-KO cells appears to be lower than those expressing the native
TCR [111]. TALEN-mediated disruption of the TRAC locus has also been combined with
PD-1 disruption to improve the activity of the CAR T cells [112]. Similarly, CRISPR/Cas9
editing of the TRAC locus has been combined with CD7 disruption to produce a fratricide
resistant “off-the shelf” CAR T cell [113]. Another approach to prevent GvHD is to express
an inhibitory form of the TCR. The truncated CD3ζ called TIM (TCR inhibitory molecule)
prevents TCR mediated cytotoxic activity against the host [114] (Figure 2). This strategy is
currently being tested in a phase 1 study involving allogeneic CAR T cells targeted against
NKG2D ligands (NCT03692429) (Table 1). As the elimination of the TCRαβ+ population is
paramount for the safety of an off-the-shelf CAR T cell, new methods are being developed
to efficiently deplete this population. Juillerat et al. have developed a new method to
produce an ultra-pure TCRαβ– population by transiently expressing a CD3 targeting CAR
on the T cells using mRNA electroporation [115,116]. This temporarily redirects the CAR T
cells to kill any CAR T cells expressing the αβTCR complex. Although this method has
only been used in a proof of principle study, it has the potential to be used in clinical CAR
T cell manufacture [115].
Although these approaches can prevent GvHD, they do not reduce immune rejec-
tion by the host. To overcome this the HLA-class 1 molecules can be removed from the
T cells [117]. To remove HLA-class 1 the Beta-2 microglobulin (B2M) gene locus can be
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disrupted as it is required for HLA-class 1 expression (Figure 2) [118–120]. Additionally,
mechanisms utilised by viruses to evade immune recognition have been investigated.
One such approach used gamma-retroviral transduction of human T cells to introduce E3
ligase transgenes into the cells. These ligase are used by human herpes virus-8 (HHV8)
to selectively ubiquinate MHC proteins to cause their trafficking away from the cell sur-
face [121,122]. Introduction of these ligase reduces NK cell targeting of CAR T cells in vitro
by removing the MHC proteins from the surface of the CAR T cells. This prevents the NK
cells recognising the MHC mismatch, thus reducing NK cell mediated destruction of the
CAR T cells [123].
It is however possible that removal of the HLA will result in NK cell recognition and
destruction of these modified T cells [118]. CD19 targeting CAR T cells with both a TRAC
and B2M gene disrupted by CRISPR/Cas9 are currently under clinical investigation for
the treatment of relapsed or refractory CD19+ leukaemia and lymphoma (NCT03166878).
Activated T cells also express HLA class II, which can be recognised by the host immune
system and cause CAR T cell destruction [124]. Triple knockout of HLA class I, HLA class
II, and T cell receptor by triple CRISPR/Cas9 targeting of the B2M, CIITA, and TRAC genes
result in better persistence in in-vivo models compared to double knock out B2M and
TRAC [119].
Sommer et al. [125] developed allogeneic CAR T cells from healthy donors that
expressed the Flt3 CAR to target AML. These cells were modified using TALENs to remove
TRAC and CD52 (Figure 2) [125]. CD52 is a glycoprotein upregulated on the cell surface of
multiple types of immune cells [126]. Anti-CD52 antibodies can be used to deplete host
immune cells to allow engraftment of the CAR T cells. Removal of CD52 from the CAR
T cells makes them resistant to this lymphodepletion so that they can persist whilst the
host immune cells are destroyed [125]. These KO cells display equivalent effector function
compared to the non-gene edited equivalents and caused a reduction in tumour burden in
an orthotopic mouse model of AML compared to control T cells [125]. This group has also
developed an allogeneic αβ CAR T cells targeting BCMA in multiple myeloma. These cells
are currently being investigated in clinical trials (NCT04093596) [127]. Similarly, a CD123
(a glycoprotein expressed on B cells) targeting CAR with TALEN-mediated inactivation of
TRAC is also being investigated in a phase 1 study in AML (NCT03114670) [128] (Table 1).
7. Induced Pluripotent Stem Cells
Another potential source of CAR T cells are induced pluripotent stem cells (iPSCs).
IPSCs can be produced from a starting cell type that is reprogrammed into a pluripotent
cell using a cocktail of small molecules and transcription factors [129–131]. Any somatic
cell can be used as the basis for an iPSC, however it has been shown that using a mature
lymphoid cell as the starting cell results in a greater number of CD4+CD8+ T cells after
iPSC differentiation [132,133].
Single clones from these reprogrammed cells are selected and expanded to produce a
master iPSC line. These cells can then be differentiated into T cells, which can be further
modified to express the CAR. One of the most attractive features of iPSCs is their unlimited
potential for division, overcoming the problem of expanding primary T cells. iPSCs are
also more amenable to genetic modification and these changes can be made to parental
cells to give rise to a modified cell line [130].
Like αβ T cells, T cells derived from iPSCs must be modified to remove molecules that
can mediate GvHD and rejection of the T cells. Due to the nature of these cells, repeated
genetic modification technically is not a major problem, though ensuring that the gene
inserts do not activate a silent proto-oncogene is a major consideration. Once modified a
single cell can be used to generate a clonal population with the desired genetic knockouts.
In addition, iPSCs derived from T cells already contain the rearranged TCR locus of the
parental cell, thus iPSCs with a particular TCR specificity can be selected for [134].
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The first clinical trial testing this approach is now underway using iPSC derived CD19
CAR T cells in patients with B cell malignancies (NCT04629729) [135]. This approach can
also be used to generate CAR NK cells in addition to CAR T cells [136].
8. Conclusions
Unfortunately, the successes of CAR T cells is yet to be widely clinically applicable.
This is due to many factors including lack of appropriate tumour specific antigens, the
immunosuppressive nature of the tumour microenvironment, variability in product quality
and high costs (previously discussed by Cutmore et al. [137]. Use of allogeneic CAR
expressing cells could overcome some of these obstacles. Allogeneic CAR products can be
made on a more industrial scale, making the production pipeline cheaper, thus rendering
the treatment more accessible to healthcare systems and more patients. Use of allogeneic
cells from healthy donors also means that the cellular product is of a higher quality and
would be available for larger numbers of patients. It would also allow for re-dosing and
more standardised dosing and activity.
This is particularly true when using cell lines such as NK-92 as they represent an
unlimited supply of donor cells. Use of allogeneic cells also means that the CAR T or
CAR NK cells can be produced in bulk and stored. This means that they are available
immediately and patients do not have to wait two–three weeks to receive the treatment.
This is especially important in cancers that progress rapidly, as using current manufacturing
protocols the disease has often progressed too much by the time the CAR T cells are ready to
be infused. Importantly, the use of allogeneic CAR T cells would also allow for targeting of
multiple antigens sequentially or simultaneously as one batch of cells could be transduced
with multiple CAR constructs as there is no limit of cell numbers obtained.
The future of CAR T cell therapy looks promising. Advances in technology and gene
editing techniques could make allogeneic “off the shelf” CAR T cells available in the near
future and could revolutionise the treatment of cancers.
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